AK137

· Akeso

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AK137, covering 2024-11-15 to 2024-11-15. Get the full timeline:

Most recent: Clinical Trial Update: AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors [Phase 1]